{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:45:10Z","timestamp":1792089910728,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,9,23]]},"DOI":"10.1038\/bjc.2014.410","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T15:58:58Z","timestamp":1406044738000},"page":"1293-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma"],"prefix":"10.1038","volume":"111","author":[{"given":"M","family":"Gkotzamanidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P P","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Kyrtopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V L","family":"Souliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"BFbjc2014410_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-009-9844-1","volume":"92","author":"T Amano","year":"2009","unstructured":"Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, Lang FF (2009) Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol 92: 357\u2013371.","journal-title":"J Neurooncol"},{"key":"BFbjc2014410_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30: 445\u2013452.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014410_CR3","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1021\/tx0499463","volume":"17","author":"S Balcome","year":"2004","unstructured":"Balcome S, Park S, Quirk Dorr DR, Hafner L, Phillips L (2004) Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards. Chem Res Toxicol 17: 950\u2013962.","journal-title":"Chem Res Toxicol"},{"key":"BFbjc2014410_CR4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","volume":"67","author":"B Barlogie","year":"1986","unstructured":"Barlogie B, Hall R, Zander A, Dicke K, Alexanian R (1986) High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67: 1298\u20131301.","journal-title":"Blood"},{"key":"BFbjc2014410_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature05268","volume":"444","author":"J Bartkova","year":"2006","unstructured":"Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, \u00d8rntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633\u2013637.","journal-title":"Nature"},{"key":"BFbjc2014410_CR6","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blad\u00e9 J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S International Myeloma Working Group (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117: 6063\u20136073.","journal-title":"Blood"},{"key":"BFbjc2014410_CR7","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311\u20135321.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014410_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/asheducation-2011.1.344","volume":"2011","author":"M Chesi","year":"2011","unstructured":"Chesi M, Bergsagel PL (2011) Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011: 344\u2013353.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbjc2014410_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","volume":"20","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Glebov O, Bergsagel PL, Kuehl WM (2007) Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20: 571\u2013596.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbjc2014410_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00018-011-0666-x","volume":"68","author":"YJ Cho","year":"2011","unstructured":"Cho YJ, Liang P (2011) S-phase-coupled apoptosis in tumor suppression. Cell Mol Life Sci 68: 1883\u20131896.","journal-title":"Cell Mol Life Sci"},{"key":"BFbjc2014410_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bcp.2008.03.025","volume":"76","author":"PH Clingen","year":"2008","unstructured":"Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 76: 19\u201327.","journal-title":"Biochem Pharmacol"},{"key":"BFbjc2014410_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrc3088","volume":"11","author":"AJ Deans","year":"2011","unstructured":"Deans AJ, West SC (2011) DNA interstrand crosslink repair and cancer. Nat Rev Cancer 11: 467\u2013480.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2014410_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3324\/haematol.11435","volume":"92","author":"MA Dimopoulos","year":"2007","unstructured":"Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP (2007) Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 92: 1505\u20131512.","journal-title":"Haematologica"},{"key":"BFbjc2014410_CR14","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2005.07.385","volume":"23","author":"MA Dimopoulos","year":"2005","unstructured":"Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP (2005) Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 23: 4381\u20134389.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014410_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbjc2014410_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/jms.1009","volume":"41","author":"M Edler","year":"2006","unstructured":"Edler M, Jakubowski N, Linscheid M (2006) Quantitative determination of melphalan DNA adducts using HPLC inductively coupled mass spectrometry. J Mass Spectrom 41: 507\u2013516.","journal-title":"J Mass Spectrom"},{"key":"BFbjc2014410_CR17","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1093\/nar\/gks670","volume":"40","author":"M Enoiu","year":"2012","unstructured":"Enoiu M, Jiricny J, Scharer OD (2012) Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Res 40: 8953\u20138964.","journal-title":"Nucleic Acids Res"},{"key":"BFbjc2014410_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mrfmmm.2011.06.012","volume":"714","author":"H Episkopou","year":"2011","unstructured":"Episkopou H, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL (2011) The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. Mutat Res 714: 78\u201387.","journal-title":"Mutat Res"},{"key":"BFbjc2014410_CR19","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1158\/0008-5472.CAN-08-3489","volume":"69","author":"H Episkopou","year":"2009","unstructured":"Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LHF, Souliotis VL (2009) Association between transcriptional activity, local chromatin structure and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. Cancer Res 69: 4424\u20134433.","journal-title":"Cancer Res"},{"key":"BFbjc2014410_CR20","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H International Myeloma Working Group (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23: 2210\u20132221.","journal-title":"Leukemia"},{"key":"BFbjc2014410_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrclinonc.2010.104","volume":"7","author":"S Giralt","year":"2010","unstructured":"Giralt S (2010) 200 mg\/m2 melphalan-the gold standard for multiple myeloma. Nat Rev Clin Oncol 7: 490\u2013491.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc2014410_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/leu.2013.284","volume":"28","author":"M Gkotzamanidou","year":"2014","unstructured":"Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL (2014) Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. Leukemia 28: 1113\u20131121.","journal-title":"Leukemia"},{"key":"BFbjc2014410_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nature03485","volume":"434","author":"VG Gorgoulis","year":"2005","unstructured":"Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907\u2013913.","journal-title":"Nature"},{"key":"BFbjc2014410_CR24","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.4161\/cc.25951","volume":"12","author":"C Gourzones-Dmitriev","year":"2013","unstructured":"Gourzones-Dmitriev C, Kassambara A, Sahota S, R\u00e8me T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B (2013) DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle 12: 2760\u20132773.","journal-title":"Cell Cycle"},{"key":"BFbjc2014410_CR25","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFbjc2014410_CR26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319: 1352\u20131355.","journal-title":"Science"},{"key":"BFbjc2014410_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4161\/trns.1.2.12788","volume":"1","author":"G Hendriks","year":"2010","unstructured":"Hendriks G, Jansen JG, Mullenders LH, de Wind N (2010) Transcription-coupled repair and apoptosis provide specific protection against transcription-associated mutagenesis by ultraviolet light. Transcription 1: 95\u201398.","journal-title":"Transcription"},{"key":"BFbjc2014410_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12185-013-1290-3","volume":"97","author":"T Hideshima","year":"2013","unstructured":"Hideshima T, Anderson KC (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 97: 324\u2013332.","journal-title":"Int J Hematol"},{"key":"BFbjc2014410_CR29","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1038\/sj.onc.1206176","volume":"21","author":"M Jasin","year":"2002","unstructured":"Jasin M (2002) Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 21: 8981\u20138993.","journal-title":"Oncogene"},{"key":"BFbjc2014410_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blad\u00e9 J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG International Myeloma Working Group (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFbjc2014410_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.dnarep.2011.04.024","volume":"10","author":"S Lagerwerf","year":"2011","unstructured":"Lagerwerf S, Vrouwe MG, Overmeer RM, Fousteri MI, Mullenders LH (2011) DNA damage response and transcription. DNA Repair (Amst) 10: 743\u2013750.","journal-title":"DNA Repair (Amst)"},{"key":"BFbjc2014410_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/sj.onc.1202356","volume":"18","author":"M Ljungman","year":"1999","unstructured":"Ljungman M, Zhang F, Chen F, Rainbow AJ, McKay BC (1999) Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18: 583\u2013592.","journal-title":"Oncogene"},{"key":"BFbjc2014410_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","volume":"300","author":"JN Matthews","year":"1990","unstructured":"Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300: 230\u2013235.","journal-title":"BMJ"},{"key":"BFbjc2014410_CR34","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/bjc.1993.419","volume":"68","author":"JA Moscow","year":"1993","unstructured":"Moscow JA, Swanson CA, Cowan KH (1993) Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 68: 732\u2013737.","journal-title":"Br J Cancer"},{"key":"BFbjc2014410_CR35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFbjc2014410_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/jphp.12072","volume":"65","author":"K Redic","year":"2013","unstructured":"Redic K (2013) Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol 65: 1095\u20131106.","journal-title":"J Pharm Pharmacol"},{"key":"BFbjc2014410_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.leukres.2013.03.006","volume":"37","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 37: 829\u2013837.","journal-title":"Leuk Res"},{"key":"BFbjc2014410_CR38","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFbjc2014410_CR39","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","volume":"113","author":"MA Shammas","year":"2009","unstructured":"Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC (2009) Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 113: 2290\u20132297.","journal-title":"Blood"},{"key":"BFbjc2014410_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/wsbm.89","volume":"2","author":"A Sharma","year":"2010","unstructured":"Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, Verma A (2010) DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2: 654\u2013669.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"BFbjc2014410_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","volume":"148","author":"EM Smith","year":"2010","unstructured":"Smith EM, Boyd K, Davies FE (2010) The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 148: 702\u2013713.","journal-title":"Br J Haematol"},{"key":"BFbjc2014410_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.dnarep.2006.05.006","volume":"5","author":"VL Souliotis","year":"2006","unstructured":"Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP (2006) Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair (Amst) 5: 972\u2013985.","journal-title":"DNA Repair (Amst)"},{"key":"BFbjc2014410_CR43","first-page":"4465","volume":"9","author":"VL Souliotis","year":"2003","unstructured":"Souliotis VL, Dimopoulos MA, Sfikakis PP (2003) Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 9: 4465\u20134474.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2014410_CR44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.V100.1.224","volume":"100","author":"VJ Spanswick","year":"2002","unstructured":"Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100: 224\u2013229.","journal-title":"Blood"},{"key":"BFbjc2014410_CR45","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1365-2125.2012.04274.x","volume":"74","author":"DT Stefanou","year":"2012","unstructured":"Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkotzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfikakis PP, Dimopoulos MA, Souliotis VL (2012) Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. Br J Clin Pharmacol 74: 842\u2013853.","journal-title":"Br J Clin Pharmacol"},{"key":"BFbjc2014410_CR46","first-page":"4313","volume":"54","author":"KD Tew","year":"1994","unstructured":"Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313\u20134320.","journal-title":"Cancer Res"},{"key":"BFbjc2014410_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mrfmmm.2009.02.003","volume":"668","author":"LH Thompson","year":"2009","unstructured":"Thompson LH, Hinz JM (2009) Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 668: 54\u201372.","journal-title":"Mutat Res"},{"key":"BFbjc2014410_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/ng.349","volume":"41","author":"G Van Haaften","year":"2009","unstructured":"Van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521\u2013523.","journal-title":"Nat Genet"},{"key":"BFbjc2014410_CR49","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/carcin\/bgh187","volume":"25","author":"MR Velangi","year":"2004","unstructured":"Velangi MR, Matheson EC, Morgan GJ, Jackson GH, Taylor PR, Hall AG, Irving JA (2004) DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 25: 1795\u20131803.","journal-title":"Carcinogenesis"},{"key":"BFbjc2014410_CR50","doi-asserted-by":"publisher","first-page":"a012625","DOI":"10.1101\/cshperspect.a012625","volume":"5","author":"W Vermeulen","year":"2013","unstructured":"Vermeulen W, Fousteri M (2013) Mammalian transcription-coupled excision repair. Cold Spring Harb Perspect Biol 5: a012625.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFbjc2014410_CR51","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/leu.2011.94","volume":"25","author":"DK Walters","year":"2011","unstructured":"Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF (2011) Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 25: 1344\u20131353.","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1038\/s41416-020-0830-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000}},{"DOI":"10.1038\/s41416-026-03646-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2014410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2014410","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bjc2014410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:33:22Z","timestamp":1792085602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2014410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9,23]]}},"alternative-id":["BFbjc2014410"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.410","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]},"assertion":[{"value":"31 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2014","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41416-026-03646-0","URL":"https:\/\/doi.org\/10.1038\/s41416-026-03646-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}